Opthea’s Wet AMD Program to be Featured at FLORetina 2024
Opthea (ASX/NASDAQ:OPT) announced that its wet age-related macular degeneration (wet AMD) therapy, sozinibercept, will be featured in an oral presentation at the FLORetina Congress in Florence, Italy, December 5-8, 2024. The presentation titled 'Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes?' will be delivered by Professor Adnan Tufail during the Retina Futura 1 session on December 6, 2024, at 11:25 AM CET.
Opthea (ASX/NASDAQ:OPT) ha annunciato che la sua terapia per la degenerazione maculare legata all'età umida (wet AMD), sozinibercept, sarà presentata in un intervento orale al FLORetina Congress a Firenze, Italia, dal 5 all'8 dicembre 2024. La presentazione, intitolata 'Oltre l'inibizione del VEGF-A: Bloccare il VEGF-C e il VEGF-D porterà a risultati migliori?', sarà tenuta dal Professor Adnan Tufail durante la sessione Retina Futura 1 il 6 dicembre 2024, alle 11:25 CET.
Opthea (ASX/NASDAQ:OPT) anunció que su terapia para la degeneración macular relacionada con la edad húmeda (wet AMD), sozinibercept, será presentada en una ponencia oral en el FLORetina Congress en Florencia, Italia, del 5 al 8 de diciembre de 2024. La presentación, titulada 'Más allá de la inhibición del VEGF-A: ¿La inhibición del VEGF-C y del VEGF-D conducirá a mejores resultados?', será impartida por el Profesor Adnan Tufail durante la sesión Retina Futura 1 el 6 de diciembre de 2024, a las 11:25 AM CET.
Opthea (ASX/NASDAQ:OPT)는 습식 노인성 황반변성(wet AMD) 치료제인 sozinibercept이 2024년 12월 5일부터 8일까지 이탈리아 피렌체에서 열리는 FLORetina Congress에서 구두 발표될 것이라고 발표했습니다. 'VEGF-A 억제를 넘어: VEGF-C와 VEGF-D의 차단이 더 나은 결과를 가져올 것인가?'라는 제목의 발표는 2024년 12월 6일 오전 11시 25분(CET) Retina Futura 1 세션에서 아드난 투파일 교수에 의해 진행될 예정입니다.
Opthea (ASX/NASDAQ:OPT) a annoncé que son traitement pour la dégénérescence maculaire liée à l'âge humide (wet AMD), sozinibercept, sera présenté lors d'une communication orale au FLORetina Congress à Florence, en Italie, du 5 au 8 décembre 2024. La présentation, intitulée 'Au-delà de l'inhibition du VEGF-A : le blocage du VEGF-C et du VEGF-D conduira-t-il à de meilleurs résultats ?', sera délivrée par le professeur Adnan Tufail lors de la session Retina Futura 1 le 6 décembre 2024 à 11h25 CET.
Opthea (ASX/NASDAQ:OPT) gab bekannt, dass ihre Therapie gegen feuchte altersbedingte Makuladegeneration (wet AMD), sozinibercept, in einer mündlichen Präsentation beim FLORetina Congress in Florenz, Italien, vom 5. bis 8. Dezember 2024 vorgestellt wird. Die Präsentation mit dem Titel 'E über die Hemmung von VEGF-A hinaus: Wird die Blockierung von VEGF-C und VEGF-D zu besseren Ergebnissen führen?' wird von Professor Adnan Tufail während der Sitzung Retina Futura 1 am 6. Dezember 2024 um 11:25 Uhr MEZ gehalten.
- None.
- None.
MELBOURNE, Australia, and Princeton, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibercept will be featured as part of an oral presentation at the annual FLORetina Congress being held on December 5-8, 2024 in Florence, Italy. FLORetina aims to provide cutting-edge insights on research and clinical development from world-leading experts in the field of medical retina, retinal surgery, and imaging.
Details are as follows:
| Session: | Retina Futura 1: Wet Age-Related Macular Degeneration (wAMD): Emerging Therapies and Clinical Updates |
| Date: | Friday, December 6, 2024, 11:25 AM CET |
| Presentation: | Beyond VEGF-A Inhibition: Will Blocking VEGF-C and VEGF-D Lead to Better Outcomes? |
| Presenter: | Professor Adnan Tufail, MBBS, MD, FRCOphth |
| Program: | https://floretina.com/floretinaicoormeeting2024/program |
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636, and ShORe, NCT04757610) for use in combination with standard-of-care anti-VEGF-A therapies to improve the overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn.
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email: info@opthea.com Web: www.opthea.com
Source: Opthea Limited
FAQ
When will Opthea's sozinibercept be presented at FLORetina 2024?
What is the topic of Opthea's (OPT) presentation at FLORetina 2024?
Who will present Opthea's (OPT) sozinibercept data at FLORetina 2024?
